FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009969591> ?p ?o ?g. }

• W2009969591 endingPage "2100" @default.
• W2009969591 startingPage "2090" @default.
• W2009969591 abstract "Preference for the Northern (N) ring conformation of the ribose moiety of nucleotide 5'-triphosphate agonists at P2Y(1), P2Y(2), P2Y(4), and P2Y(11) receptors, but not P2Y(6) receptors, was established using a ring-constrained methanocarba (a 3.1.0-bicyclohexane) ring as a ribose substitute (Kim et al. J. Med. Chem. 2002, 45, 208-218.). We have now combined the ring-constrained (N)-methanocarba modification of adenine nucleotides with other functionalities known to enhance potency at P2 receptors. The potency of the newly synthesized analogues was determined in the stimulation of phospholipase C through activation of turkey erythrocyte P2Y(1) or human P2Y(1) and P2Y(2) receptors stably expressed in astrocytoma cells. An (N)-methanocarba-2-methylthio-ADP analogue displayed an EC(50) at the hP2Y(1) receptor of 0.40 nM and was 55-fold more potent than the corresponding triphosphate and 16-fold more potent than the riboside 5'-diphosphate. 2-Cl-(N)-methanocarba-ATP and its N(6)-Me analogue were also highly selective, full agonists at P2Y(1) receptors. The (N)-methanocarba-2-methylthio and 2-chloromonophosphate analogues were full agonists exhibiting micromolar potency at P2Y(1) receptors, while the corresponding ribosides were inactive. Although beta,gamma-methylene-ATP was inactive at P2Y receptors, beta,gamma-methylene-(N)-methanocarba-ATP was a potent hP2Y(1) receptor agonist with an EC(50) of 160 nM and was selective versus hP2Y(2) and hP2Y(4) receptors. The rates of hydrolysis of Northern (N) and Southern (S) methanocarba analogues of AMP by rat 5'-ectonucleotidase were negligible. The rates of hydrolysis of the corresponding triphosphates by recombinant rat NTPDase1 and 2 were studied. Both isomers were hydrolyzed by NTPDase 1 at about half the rate of ATP hydrolysis. The (N) isomer was hardly hydrolyzed by NTPDase 2, while the (S) isomer was hydrolyzed at one-third of the rate of ATP hydrolysis. This suggests that new, more stable and selective nucleotide agonists may be designed on the basis of the (N)-conformation, which greatly enhanced potency at P2Y(1) receptors." @default.
• W2009969591 created "2016-06-24" @default.
• W2009969591 creator A5020809391 @default.
• W2009969591 creator A5030808105 @default.
• W2009969591 creator A5034951384 @default.
• W2009969591 creator A5047815614 @default.
• W2009969591 creator A5050544457 @default.
• W2009969591 creator A5053282863 @default.
• W2009969591 creator A5059206725 @default.
• W2009969591 creator A5078029660 @default.
• W2009969591 creator A5091587615 @default.
• W2009969591 date "2002-04-12" @default.
• W2009969591 modified "2023-10-16" @default.
• W2009969591 title "Adenine Nucleotide Analogues Locked in a Northern Methanocarba Conformation: Enhanced Stability and Potency as P2Y₁ Receptor Agonists" @default.
• W2009969591 cites W130048390 @default.
• W2009969591 cites W1513653241 @default.
• W2009969591 cites W1516729867 @default.
• W2009969591 cites W1608256683 @default.
• W2009969591 cites W1847464474 @default.
• W2009969591 cites W1902132075 @default.
• W2009969591 cites W1975596197 @default.
• W2009969591 cites W1983794537 @default.
• W2009969591 cites W1986775812 @default.
• W2009969591 cites W1991433173 @default.
• W2009969591 cites W2001759023 @default.
• W2009969591 cites W2001777306 @default.
• W2009969591 cites W2005786584 @default.
• W2009969591 cites W2005970127 @default.
• W2009969591 cites W2006385943 @default.
• W2009969591 cites W2008808395 @default.
• W2009969591 cites W2010703904 @default.
• W2009969591 cites W2013428743 @default.
• W2009969591 cites W2019034011 @default.
• W2009969591 cites W2022703044 @default.
• W2009969591 cites W2025781453 @default.
• W2009969591 cites W2030204779 @default.
• W2009969591 cites W2030345023 @default.
• W2009969591 cites W2035974703 @default.
• W2009969591 cites W2037125571 @default.
• W2009969591 cites W2037935243 @default.
• W2009969591 cites W2042933688 @default.
• W2009969591 cites W2044304093 @default.
• W2009969591 cites W2051626166 @default.
• W2009969591 cites W2054047850 @default.
• W2009969591 cites W2057947793 @default.
• W2009969591 cites W2064566190 @default.
• W2009969591 cites W2066040631 @default.
• W2009969591 cites W2075524088 @default.
• W2009969591 cites W2088530528 @default.
• W2009969591 cites W2100447139 @default.
• W2009969591 cites W2100799786 @default.
• W2009969591 cites W2102223391 @default.
• W2009969591 cites W2104419986 @default.
• W2009969591 cites W2144662243 @default.
• W2009969591 cites W2150030148 @default.
• W2009969591 cites W2158833117 @default.
• W2009969591 cites W2208774673 @default.
• W2009969591 cites W2325337907 @default.
• W2009969591 cites W2416001729 @default.
• W2009969591 cites W2950689316 @default.
• W2009969591 cites W2952734518 @default.
• W2009969591 doi "https://doi.org/10.1021/jm010538v" @default.
• W2009969591 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4959107" @default.
• W2009969591 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11985476" @default.
• W2009969591 hasPublicationYear "2002" @default.
• W2009969591 type Work @default.
• W2009969591 sameAs 2009969591 @default.
• W2009969591 citedByCount "58" @default.
• W2009969591 countsByYear W20099695912012 @default.
• W2009969591 countsByYear W20099695912013 @default.
• W2009969591 countsByYear W20099695912014 @default.
• W2009969591 countsByYear W20099695912016 @default.
• W2009969591 countsByYear W20099695912017 @default.
• W2009969591 countsByYear W20099695912019 @default.
• W2009969591 countsByYear W20099695912020 @default.
• W2009969591 countsByYear W20099695912021 @default.
• W2009969591 countsByYear W20099695912022 @default.
• W2009969591 crossrefType "journal-article" @default.
• W2009969591 hasAuthorship W2009969591A5020809391 @default.
• W2009969591 hasAuthorship W2009969591A5030808105 @default.
• W2009969591 hasAuthorship W2009969591A5034951384 @default.
• W2009969591 hasAuthorship W2009969591A5047815614 @default.
• W2009969591 hasAuthorship W2009969591A5050544457 @default.
• W2009969591 hasAuthorship W2009969591A5053282863 @default.
• W2009969591 hasAuthorship W2009969591A5059206725 @default.
• W2009969591 hasAuthorship W2009969591A5078029660 @default.
• W2009969591 hasAuthorship W2009969591A5091587615 @default.
• W2009969591 hasBestOaLocation W20099695912 @default.
• W2009969591 hasConcept C104317684 @default.
• W2009969591 hasConcept C160225129 @default.
• W2009969591 hasConcept C166342909 @default.
• W2009969591 hasConcept C170493617 @default.
• W2009969591 hasConcept C181199279 @default.
• W2009969591 hasConcept C185592680 @default.
• W2009969591 hasConcept C2778938600 @default.
• W2009969591 hasConcept C2779461342 @default.
• W2009969591 hasConcept C512185932 @default.
• W2009969591 hasConcept C55493867 @default.

• next